550 results found

This paper was originally submitted to the American Intellectual Property Law Association (AIPLA) ahead of its 2021 Annual Meeting and was the subject of a presentation at a plenary session there on 28 October 2021.

An orphan drug, or orphan medicinal product, is a medicine that is developed to treat a rare disease, defined as a disease affecting a relatively small number of people as a proportion of the population.

In our previous discussions of antibody practice at the EPO, we observed that there was a (perhaps surprising) lack of case law to support the evolving practice of the examining divisions

Before the EPO parameters are defined as features which are based on directly measurable properties or combinations of several variables in the form of formulae.

Earlier this year, the World Health Organisation (WHO) declared COVID-19 to no longer constitute a public health emergency of international concern.

Which new ideas are worthy of a patent application? How should the applications be drafted and prosecuted? When should they be filed? Where in the world should they be filed?

Which new ideas are worthy of a patent application? How should the applications be drafted and prosecuted?

Welcome to the latest edition of J A Kemp's annual review of EPO Board of Appeal decisions concerning antibody inventions. In this update, we examine decisions issued between 31 January 2025 and 31 December 2025.

Obtaining patents for polymorphs can be challenging. However, before the European Patent Office, there is no general rule which makes polymorphs less patentable in principle than other subject matter.

Parameters are characteristic values of a product or process which are generally based on directly measurable properties.

Three years after the Enlarged Board's G2/21 decision on post-filed data in inventive step assessments, European patent practitioners face continued uncertainty as Boards of Appeal interpret the ruling inconsistently.

A Unitary Patent may be obtained from any European Patent Office (EPO) application that has a filing date of 1 March 2007 or later. Following grant of a European Patent based on such an application...

This briefing explores the options available to applicants in the event that the deadline for filing a PCT has been missed.

Re-establishment of rights under Article 122 EPC may be used to recover rights lost as a result of missing a deadline set by the European Patent Office.

The Enlarged Board of Appeal of the EPO has, in case G 01/19 (Pedestrian simulation), issued a decision regarding the patentability of simulations under the EPC.

Welcome to the latest edition of the J A Kemp annual review of EPO Board of Appeal decisions relating to antibody inventions.

European Patent Office (EPO) opposition procedure comprises two parts: opposition division (first instance), and, if relevant, appeal.

The deadline for requesting entry of a PCT application into the European regional phase is 31 months from the filing date or, if priority has been claimed, from the priority date (Rule 159(1) EPC).